Are codes J2274 and S9328 medically necessary for a patient with Chronic Pain Syndrome (G89.4) who has an implanted intrathecal pain pump?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Medical Necessity of J2274 and S9328 for Intrathecal Pain Pump Refill in Chronic Pain Syndrome

Yes, codes J2274 (morphine sulfate injection) and S9328 (home infusion therapy supplies) are medically necessary for this patient with chronic pain syndrome who has an established intrathecal pain pump providing effective pain relief. 1

Rationale for Medical Necessity

Established Guideline Support for Intrathecal Opioid Therapy

The American Society of Anesthesiologists (ASA) explicitly states that intrathecal opioid injection or infusion may be used for neuropathic pain patients as part of chronic pain management. 1 This directly supports the use of morphine sulfate (J2274) delivered via the implanted pump for this patient's chronic pain syndrome.

Supplies Are Integral to DME Function

The clinical policy bulletin criteria you referenced correctly identifies that supplies and drugs used with implantable infusion pumps are considered medically necessary when they are needed for the effective use of the DME or to assure proper functioning of the equipment. The morphine sulfate medication (J2274) must be placed directly into the pump to achieve therapeutic benefit, and the home infusion therapy supplies (S9328) are required for pump maintenance and refills.

Patient Meets Established Criteria

Based on the clinical documentation provided:

  • The patient has an established intrathecal pump that is providing effective pain relief - this indicates prior successful trial and psychological evaluation were completed 1
  • The pump is described as "an integral part of the patient's management program" - confirming ongoing medical necessity
  • The device delivers precise medication doses offering effective pain relief - demonstrating therapeutic benefit

Coding Justification

J2274 (Morphine Sulfate Injection)

  • This code represents the actual medication (morphine sulfate 10 mg/mL) being delivered intrathecally 1
  • The 480 units requested for one year of therapy is reasonable for continuous intrathecal infusion
  • Intrathecal opioids are specifically endorsed by ASA guidelines for chronic pain management 1

S9328 (Home Infusion Therapy Supplies)

  • These supplies are necessary for the proper functioning and maintenance of the implanted pump
  • The 365 units (daily supplies for one year) align with standard pump refill and maintenance requirements
  • Without these supplies, the pump cannot be safely refilled or maintained

Critical Considerations

Prior Authorization History

The patient has previous certifications for this therapy (references 7192230 and 6201931), establishing a pattern of medical necessity and effective treatment. Continuation of proven effective therapy is appropriate. 1

Multimodal Treatment Context

Intrathecal opioid therapy should be part of a multimodal pain management strategy, not standalone treatment. 1 The documentation should ideally reflect what other modalities are being used (physical therapy, psychological support, etc.), though the pump's established effectiveness supports continuation.

Monitoring Requirements

A strategy for monitoring side effects, adverse effects, and compliance should be in place before prescribing long-term pharmacologic therapy. 1 The ongoing pump refills provide regular touchpoints for this monitoring.

Common Pitfalls to Avoid

  • Do not deny based on lack of "specific criteria for J2274" - the medication is the therapeutic agent required for the already-approved pump (DME)
  • Do not require re-demonstration of trial efficacy - the pump is established and providing effective relief
  • Do not separate the medication from the device - they function as an integrated system per DME supply guidelines

Shared Decision-Making Documentation

While not explicitly documented in your request, shared decision-making regarding intrathecal opioid therapy should include specific discussion of potential complications. 1 This should have been addressed at initial implantation but bears ongoing consideration.

The medical necessity is established through the combination of guideline support for intrathecal opioids in chronic pain, the pump's documented effectiveness, and the classification of these supplies/medications as integral to approved DME function.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.